Research programme: diabetes therapy - Verva Pharmaceuticals

Drug Profile

Research programme: diabetes therapy - Verva Pharmaceuticals

Alternative Names: VVP 100X

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator
  • Developer Verva Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Australia
  • 20 Jul 2015 Reverx acquires diabetes therapeutics from Verva Pharmaceuticals
  • 11 Sep 2008 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top